Replimune Shares Surge Ahead of Key FDA Decision Date

Investors in Replimune are positioning for a potential resolution to a prolonged period of uncertainty. The company’s stock price advanced by nearly eleven percent last Friday, just ahead of a critical regulatory milestone. The biotechnology sector is now focused on April 10, when the U.S. Food and Drug Administration (FDA) is set to deliver its verdict on the approval of the melanoma therapy RP1.

Financial Position and Strategic Preparations

From a financial standpoint, Replimune appears well-capitalized for the road ahead. The company reported cash and equivalents of $269.1 million as of the end of 2025. Management projects these reserves are sufficient to fund operations through the first quarter of 2027. A favorable FDA decision would also unlock access to an additional $120 million under an existing loan agreement with Hercules Capital.

These funds support substantial research and development efforts, with quarterly R&D expenses reaching $53.1 million in the final quarter of 2025 alone. These costs reflect the advanced stage of the company’s clinical programs. Beyond its lead melanoma indication, the company is advancing its RPx platform for other cancer types to broaden its development pipeline.

Preparations for a potential commercial launch are already underway in the background. The upcoming April decision represents a potential inflection point, transitioning Replimune from a clinical-stage research entity to a commercial-stage biopharmaceutical company.

Should investors sell immediately? Or is it worth buying Replimune?

A Second Attempt at Regulatory Approval

The path to this decision has been challenging. The FDA issued a rejection for RP1 in July 2025, citing concerns over the clinical interpretability of data from the IGNYTE trial. In response, Replimune submitted additional data in October 2025 to further substantiate the efficacy of RP1 in combination with nivolumab for treating advanced cutaneous melanoma.

Market observers interpreted Friday’s trading activity as a clear signal of growing investor confidence. Trading volume nearly doubled to 3.18 million shares. During the session, the equity traded between $7.51 and $8.43 before closing at $8.24.

A central component of the company’s regulatory strategy has been the initiation of the confirmatory Phase 3 trial, IGNYTE-3. This study is viewed as essential for pursuing an accelerated approval pathway. Regardless of the immediate outcome on April 10, management has already commenced this next phase of clinical validation for its lead candidate.